United States· US:0006-3066_428f7828-6d1c-438b-a17d-b4af0700c740
EMEND
A aprepitant product containing aprepitant, registered in United States by Merck Sharp & Dohme LLC. The same ATC class is registered in 17 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Aprepitant is registered in 17 of 19 countries.
Countries holding a registration under ATC A04AD12 (aprepitant), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Aprepitant · ATC A04AD12
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of aprepitant costs, country by country.
Normalised to the WHO defined daily dose (165 mg), the median price runs from $0.40 in Finland to $157.48 in United States — a ×394 gap.
- United States: $157.48 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Aprepitant · price per daily dose (165 mg)
USD · FX 28 Sept 2026
- US United States$157.48 (acquisition cost)
- CH Switzerland$73.26
- FR France$33.15
- FI Finland$0.40
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- APREPITANT
- Manufacturer
- Merck Sharp & Dohme LLC
- Country
- United States (US)
- ATC code
- A04AD12
- ATC class
- Aprepitant
- Defined daily dose
- 165 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1100063066031 POUCH in 1 CARTON (0006-3066-03) / 1 POWDER, FOR SUSPENSION in 1 POUCH (0006-3066-01)
- ndc110006-3066-03
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
583 interactions on record for aprepitant.
Graded by severity as the source publishes them — 73 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Aprepitant · interactions on record
583 records
- 73 severe
- 380 moderate
- 25 minor
- 104 info
Most severe, free to view
- CisaprideA03FA02severe
- NaloxegolA06AH03severe
- EliglustatA16AX10severe
- LonafarnibA16AX20severe
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Aprepitant in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumEmend 125 mgMerck Sharp & Dohme
- CzechiaEMENDMerck Sharp & Dohme B.V., Haarlem
- SpainEMEND 125 MG POLVO PARA SUSPENSION ORALMerck Sharp & Dohme B.V.
- FinlandEmendMerck Sharp & Dohme B.V.
- FranceEMEND 125 mg, poudre pour suspension buvableMERCK SHARP & DOHME (PAYS-BAS)
- United KingdomEmend 125mg oral powder sachetsMerck Sharp & Dohme (UK) Ltd
- IrelandEmend 125 mg powder for oral suspensionMerck Sharp & Dohme BV,
- IcelandEmendMerck Sharp & Dohme B.V.*
Authorised across Europe · EMA
The same active substance is authorised in 27 EEA countries. Names it is sold under:
- Austria · Aprepitant Accord, Aprepitant Ratiopharm
- Belgium · Aprepitant Sandoz, Aprepitant Teva
- Cyprus · Atanto, Endrem
- Czechia · Aprepitant Accord, Aprepitant Sandoz
- Germany · Aprepilor, Aprepitant Al
- Denmark · Aprepitant "medical Valley", Aprepitant Medical Valley
- Estonia · Aprepitant Sandoz
- Spain · Aprepitant Accord, Aprepitant Qilu
- Finland · Aprepitant Stada
- France · Aprepitant Accord, Aprepitant Aprepitant
- United Kingdom (Northern Ireland) · Aprepitant, Aprepitant Accord
- Greece · Aprepitant Win Medica, Atanto
- Croatia · Aprepitant Alpha-Medical, Aprepitant Sandoz
- Hungary · Aprepitant Pharmacenter, Aprepitant Q Pharma
- Ireland · Aprepitant Accord
- Iceland · Aprepitant Medical Valley, Aprepitant Stada
- Italy · Aprepitant Accord, Aprepitant Teva
- Liechtenstein · Emend
- Lithuania · Aprepitant Sandoz
- Latvia · Aprepitant Sandoz
- Netherlands · Aprepitant Accord, Aprepitant Aurobind
- Norway · Emend
- Poland · Aprepitant Accord, Aprepitant Sandoz
- Portugal · Aprepitant Generis
- Sweden · Aprepitant Medical Valley, Aprepitant Stada
- Slovenia · Aprepitant Teva
- Slovakia · Aprepitant, Aprepitant Stada
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c6b564e0-0fcf-458c-ac54-02db9bca14a5 GET /v1/drugs/c6b564e0-0fcf-458c-ac54-02db9bca14a5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "125",
"substance": "APREPITANT",
"productndc": "0006-3066",
"dosage_form": "POWDER, FOR SUSPENSION",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA207865",
"marketing_category": "NDA"
}See everything about aprepitant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.